AEterna Zentaris (AEterna Zentaris) EV-to-EBIT : 1.35 (As of Apr. 26, 2024)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AEterna Zentaris's Enterprise Value is $-24.27 Mil. AEterna Zentaris's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-18.01 Mil. Therefore, AEterna Zentaris's EV-to-EBIT for today is 1.35.

The historical rank and industry rank for AEterna Zentaris's EV-to-EBIT or its related term are showing as below:

AEZS' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.54 Med: -0.19 Max: 7.95
Current: 1.35

During the past 13 years, the highest EV-to-EBIT of AEterna Zentaris was 7.95. The lowest was -13.54. And the median was -0.19.

AEZS's EV-to-EBIT is ranked better than
61.76% of 442 companies
in the Biotechnology industry
Industry Median: 8.41 vs AEZS: 1.35

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. AEterna Zentaris's Enterprise Value for the quarter that ended in Dec. 2023 was $-24.71 Mil. AEterna Zentaris's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-18.01 Mil. AEterna Zentaris's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 72.89%.

AEterna Zentaris EV-to-EBIT Historical Data

The historical data trend for AEterna Zentaris's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris EV-to-EBIT Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-1.17

-0.59

2.54

2.30

1.36

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															2.30	2.19	1.98	1.69	1.36

Competitive Comparison of AEterna Zentaris's EV-to-EBIT

For the Biotechnology subindustry, AEterna Zentaris's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's EV-to-EBIT falls into.

AEterna Zentaris EV-to-EBIT Calculation

AEterna Zentaris's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-24.268	/	-18.008
	=	1.35

AEterna Zentaris's current Enterprise Value is $-24.27 Mil.
AEterna Zentaris's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.01 Mil.

AEterna Zentaris (NAS:AEZS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

AEterna Zentaris's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-18.008	/	-24.7050632
	=	72.89 %

AEterna Zentaris's Enterprise Value for the quarter that ended in Dec. 2023 was $-24.71 Mil.
AEterna Zentaris's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.01 Mil.

AEterna Zentaris EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.